Everything small molecule drug discovery should be.

About Terray

We invented a different way

Terray exists to change the way experimentation and computation work together. We believe high-quality data at scale is the key to unlocking generative AI for small molecules. Our workflow places equal emphasis on wet lab science and AI, giving us everything we need to solve the toughest therapeutic challenges.
About our company
Computer Engineers Working
Our Approach

A platform intentionally designed to improve the speed, cost, and success rate of small molecule drug discovery and development.

Explore our platform
Unparalleled Scale and Speed Icon

Unparalleled Scale and Speed

Our experimental dataset includes more than two billion unique target-ligand binding measurements, growing by 150 million new measurements every month.
Precise Data Icon

Precise Data

Each measurement is supported by an average of 25 independent data points, resulting in high resolution quantitative data that unlocks accurate molecular property prediction with deep learning regression models.
Closed-loop Iteration Icon

Closed-loop Iteration

A design-make-test-analyze cycle takes less than a month per target, enabling us to intelligently and smoothly explore chemical space, experimentally measuring millions of molecules at a time.
Data Rich Target Prioritization Icon

Data Rich Target Prioritization

Our platform rapidly identifies potent, selective small molecules for many targets in parallel, enabling us to evaluate multiple points of intervention in a pathway to treat disease.
Pipeline Icon


Our internal pipeline is focused on immunology. In partnership, we apply our platform to a wide range of challenging targets and therapeutic areas with large pharma and biotech.
Scientists work in lab
Join us

Our team is deeply curious, seriously inventive, and driven by data. Sound like you?

See open roles
Latest news & press

Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb

December 14, 2023

Terray Therapeutics Announces Investment from NVIDIA to Enable Generative AI Design for Drug Discovery

November 9, 2023

Terray Therapeutics Strengthens Leadership with Appointment of Sudha Parasuraman, MD to its Board of Directors

May 16, 2023
© 2024 Terray Therapeutics, Inc.